Literature DB >> 20510734

BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis.

Katia Basso1, Riccardo Dalla-Favera.   

Abstract

BCL6 is a transcriptional repressor which has emerged as a critical regulator of germinal centers (GC), the sites where B cells are selected based on the production of antibodies with high affinity for the antigen. BCL6 is also a frequently activated oncogene in the pathogenesis of human B cell lymphomas, most of which derive from the GC B cells. A thorough understanding of the biological role of BCL6 in normal B cell development and lymphomagenesis depends upon the identification of the full set of genes that are targets of its transcriptional regulatory function. Recently, the identification of BCL6 targets has been implemented with the use of genome-wide chromatin immunoprecipitation and gene expression profiling approaches. A large set of promoters have been shown to be physically bound by BCL6, but only a fraction of them appears to be subjected to transcriptional repression in GC B cells. This set of BCL6 targets points to a number of cellular functions which are likely to be directly controlled by BCL6 during GC development, including activation, survival, DNA-damage response, cell cycle arrest, cytokine-, toll-like receptor-, TGFbeta-, WNT-signaling, and differentiation. Overall, BCL6 is revealing its dual role of "safe-keeper" in preventing centroblasts from responding to signals leading to a premature exit from the GC and of contributor to lymphomagenesis by allowing the instauration of conditions favorable to malignant transformation. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20510734     DOI: 10.1016/S0065-2776(10)05007-8

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  120 in total

1.  Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses.

Authors:  Clayton A White; Egest J Pone; Tonika Lam; Connie Tat; Ken L Hayama; Guideng Li; Hong Zan; Paolo Casali
Journal:  J Immunol       Date:  2014-11-12       Impact factor: 5.422

2.  Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma.

Authors:  Murali Janakiram; Venu K Thirukonda; Matthew Sullivan; Adam M Petrich
Journal:  Curr Treat Options Oncol       Date:  2012-02-02

Review 3.  EBV Persistence--Introducing the Virus.

Authors:  David A Thorley-Lawson
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

4.  Bone marrow stromal cells induced activation of nuclear factor κB signaling protects non-Hodgkin's B lymphoma cells from apoptosis.

Authors:  Tuo Su; Jiakai Li; Mingming Meng; Sheng Zhao; Yali Xu; Xinmin Ding; Hong Jiang; Xiaorong Ma; Jin Qian; Wei Han; Lixin Sun; Xiaobin Li; Zuojun Liu; Lei Pan; Xinying Xue
Journal:  Tumour Biol       Date:  2016-02-12

5.  Function of B-cell lymphoma 6 in trophoblast cells.

Authors:  Jie Li; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 6.  Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.

Authors:  Zijun Y Xu-Monette; L Jeffrey Medeiros; Yong Li; Robert Z Orlowski; Michael Andreeff; Carlos E Bueso-Ramos; Timothy C Greiner; Timothy J McDonnell; Ken H Young
Journal:  Blood       Date:  2012-01-24       Impact factor: 22.113

7.  AID-associated DNA repair pathways regulate malignant transformation in a murine model of BCL6-driven diffuse large B-cell lymphoma.

Authors:  Xiwen Gu; Carmen J Booth; Zongzhi Liu; Matthew P Strout
Journal:  Blood       Date:  2015-09-18       Impact factor: 22.113

Review 8.  Diffuse large B-cell lymphoma-treatment approaches in the molecular era.

Authors:  Mark Roschewski; Louis M Staudt; Wyndham H Wilson
Journal:  Nat Rev Clin Oncol       Date:  2013-11-12       Impact factor: 66.675

9.  BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.

Authors:  Jie Ding; Wilhelm G Dirks; Stefan Ehrentraut; Robert Geffers; Roderick A F MacLeod; Stefan Nagel; Claudia Pommerenke; Julia Romani; Michaela Scherr; Lea A I Vaas; Margarete Zaborski; Hans G Drexler; Hilmar Quentmeier
Journal:  Haematologica       Date:  2015-03-13       Impact factor: 9.941

10.  Downregulation of FOXP1 is required during germinal center B-cell function.

Authors:  Ainara Sagardoy; Jose I Martinez-Ferrandis; Sergio Roa; Karen L Bunting; María Angela Aznar; Olivier Elemento; Rita Shaknovich; Lorena Fontán; Vicente Fresquet; Ignacio Perez-Roger; Eloy F Robles; Linde De Smedt; Xavier Sagaert; Ari Melnick; Jose A Martinez-Climent
Journal:  Blood       Date:  2013-04-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.